Sun Pharma Latest Updates

$SUNPHARMA Q4 FY26 Net Profit Surges 26% YoY Sun Pharmaceutical Industries Limited reported a robust 26.2% year-on-year growth in consolidated net profit, reaching ₹2,714 crore for the fourth quarter ended March 31, 2026, compared to ₹2,150 crore in Q4 FY25. Revenue from operations for the quarter grew 12.8% year-on-year to hit ₹14,612 crore. On a sequential basis, however, net profit moderated by 19.4% and revenue dipped 5.9% compared to the December quarter. Full-Year FY26 Earnings and Exceptional Gains For the complete financial year 2025-26, the pharmaceutical major clocked a 5% increase in annual net profit to reach ₹11,479.4 crore, backed by an 11.9% year-on-year rise in consolidated revenue to ₹58,220.1 crore. The full-year bottom line was heavily bolstered by one-time exceptional gains totaling approximately ₹1,700 crore, which included a direct exceptional item credit of ₹1,307.5 crore alongside an exceptional tax credit of ₹385.4 crore. Operating Margins and High R&D Allocation The company recorded an EBITDA of ₹3,955 crore for Q4 FY26, marking a 6.4% year-on-year increase. However, the quarterly EBITDA margin compressed slightly to 27.1% from 28.7% in Q4 FY25 due to a shifting product mix and elevated logistical inputs. For the full year, the company maintained an efficient cost matrix with an annual EBITDA margin of 30.3%, spending ₹35,540 crore (6.1% of sales) on core research and development (R&D) activities. Global Clinical Trial Data Disclosed at ASCO 2026 At the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, Sun Pharma presented updated clinical data from the pivotal trial of UNLOXCYT (cosibelimab), targeting advanced cutaneous squamous cell carcinoma. The drug demonstrated a 50% objective response rate across 64 evaluated patients, with a complete response achieved by 27% of participants and a manageable, low-grade adverse effect profile.